MIMEDX GROUP, INC.

MiMedx Group develops and distributes placental tissue allografts for wound care, surgical, and burn applications. The company processes human placental tissues—including the amniotic membrane, umbilical cord, and placental disc—using its proprietary PURION process, which combines aseptic processing and terminal sterilization while preserving the tissue's inherent biological properties, regulatory proteins, cytokines, chemokines, and growth factors. This processing approach is covered by patents and proprietary methods.

The company's wound care portfolio includes EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets, which function as protective barriers and are available in multiple sizes to minimize product waste. Its surgical and other offerings comprise AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT, which serve applications in lower extremity repair, plastic surgery, vascular surgery, and orthopedic procedures.

MiMedx operates with approximately 808 full-time employees and maintains headquarters in Marietta, Georgia. The company distributes products in the United States through a direct sales force, independent sales agents, and independent distributors. It also maintains a strategic alliance with Vaporox, Inc. to promote its wound care offerings. The company was founded in 2006.